Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about using tretinoin to improve the response to Minoxidil for hair loss treatment. No specific protocol for tretinoin application is provided.

The conversation discusses using PGE2 as a hair growth stimulant, comparing it to minoxidil, and considering the addition of Setipiprant. Concerns about side effects like skin damage and cost are also mentioned.

The conversation discusses hair regrowth using RU58841 and Minoxidil in the morning, and Minoxidil with needle massage in the evening. The user is inquiring if there are signs of hair regrowth by comparing photos from September 3 to recent ones.

Cold shock therapy may promote hair growth, but cold alone is not effective. Combining treatments like minoxidil, finasteride, cold showers, spicy foods, and exercise may enhance results.

PP405 is a potential hair loss treatment that may reactivate dormant hair follicles, with Phase 3 trials expected. Some users are cautious, suggesting using finasteride in the meantime, while others are skeptical about PP405's effectiveness.

A 17-year-old is addressing hair loss with finasteride, topical minoxidil, and microneedling. They are considering adding GHK-Cu to their regimen, but others advise caution with finasteride due to age.

MCL-1 is important for hair follicle stem cell survival, but its impact on human hair regrowth is unclear. Minoxidil and finasteride are the main treatments, with doubts about new discoveries leading to effective human solutions soon.

PP405 shows promise in hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil, with significant results in just four weeks. The treatment is still in early stages, with further trials needed to determine its long-term effectiveness and optimal dosage.

Male pattern baldness (MPB) may be an early warning sign for type 2 diabetes due to its association with insulin resistance. Treatments discussed include testosterone therapy and finasteride, which affects hormone levels related to hair loss and insulin sensitivity.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

The conversation discusses using microneedling with growth factor serum, PRF injections, dutasteride, oral and topical minoxidil, and topical exosomes to treat hair loss, particularly on the crown. OP plans to microneedle twice a month and seeks feedback on Korean growth factor serums.

Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.

A user is considering using compounded Minoxidil with Tretinoin from Medical Wellness Center to improve hair growth. They are also curious about the effects of higher Minoxidil doses and adding Tretinoin to their regimen.

The user has been using a hair loss treatment protocol including topical dutasteride, minoxidil with tretinoin, ketoconazole shampoo, microneedling, a laser cap, and vitamin D for 15 weeks, showing impressive progress. Feedback suggests continuing medical therapy for 12-24 months before considering a hair transplant.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

The user experiences side effects from minoxidil and is considering alternatives like stemoxydine and adenosine for hair regrowth and density, but finds options like caffeine and various oils unreliable. They are also using a 5AR inhibitor (finasteride).

A user found a successful hair loss treatment using a combination of finasteride, dutasteride, minoxidil, and RU58841. They plan to switch to a purely topical regimen with finasteride, RU58841, and minoxidil.

Fatty acid metabolic signaling can activate epithelial stem cells for hair regeneration. Oleic and palmitoleic acids showed the best results, but practical application on humans remains uncertain.

Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.

Applying Epidermal Growth Factor (EGF) topically may improve skin and potentially promote scalp health and hair growth, especially after microneedling. The user shares their positive experience with EGF and provides a product link.

The user is considering changing their hair loss treatment from topical minoxidil and oral finasteride to oral minoxidil and oral dutasteride, with suggestions to add microneedling and possibly red light therapy. They are also exploring the addition of a caffeine and adenosine mix to their regimen.

Hair loss is linked to cellular physiology and the IGF-1 to TGF-B1 ratio, not just androgen sensitivity. The theory lacks evidence, while finasteride and minoxidil are effective treatments.

A user did not respond to finasteride, dutasteride, and oral minoxidil for hair loss after four years of treatment and is considering scalp micropigmentation (SMP). Other users suggest the hair loss pattern may indicate alopecia areata and recommend seeing a dermatologist.

A 48-year-old who had been thinning since 25 and reached NW4-5 baldness saw no improvement with 1mg/day finasteride and 5% minoxidil twice a day after 8 months. After copying another person's routine, they now use 0.5mg finasteride, ketoconazole shampoo weekly, daily microneedling with 0.5mm and 1mm once a week, and apply minoxidil twice daily, resulting in baby hairs on their bald spot and temples after three months.

PP405 shows promise for hair regrowth, with new hairs observed in 66% of patients in just 27 days. The discussion also mentions Minoxidil, finasteride, and RU58841 as potential treatments.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

The conversation is about a transgender individual's experience with hair regrowth using topical minoxidil and hormone replacement therapy (HRT), expressing concern about the slow growth and thin appearance of their hair. Some responses encourage patience and highlight the variability of results, while others discuss the role of HRT and its effects.

DHT may inhibit hair growth by affecting mitochondrial function, leading to hair follicle miniaturization. Treatments like minoxidil and PP405 may promote hair growth by altering metabolic pathways, potentially counteracting DHT's effects.

PP405 shows significantly better early-stage hair regrowth results compared to minoxidil and finasteride, with 31% of users experiencing over 20% density increase in 4–8 weeks. Minoxidil and finasteride show minimal or no visible regrowth in the same timeframe.

A user is seeking a Minoxidil Response Test kit in the EU without bundled consultations. They mention alternatives like oral minoxidil and tretinoin but prefer the test alone.